MiR-106a is an independent prognostic marker in patients with glioblastoma

Neuro-Oncology

Volumn 15, Issue 6, 2013, Pages 707-717

  Zhao, Shiguang ^a,b   Yang, Guang ^a,b   Mu, Yulong ^a,b   Han, Dayong ^a,b   Shi, Chen ^c   Chen, Xin ^a,b   Deng, Yifan ^a,b   Zhang, Daming ^a,b   Wang, Lu ^b   Liu, Yaohua ^a   Hou, Xu ^a,b   Wang, Chunlei ^a,b   Wu, Jianing ^a,b   Liu, Huailei ^a,b   Wang, Ligang ^a,b   Zhang, Guang ^a,b   Qi, Jiping ^a   Fang, Xiang ^a   Shi, Changbin ^d   Ai, Jing ^b  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

FFPE; glioblastoma; miR 106a; prognosis; prognostic marker

Indexed keywords

BIOLOGICAL MARKER; ISOCITRATE DEHYDROGENASE 1; MICRORNA; MICRORNA 106A; PROTEIN P53; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; FORMALIN FIXED PARAFFIN EMBEDDED TISSUE SECTION; FROZEN SECTION; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; ROOM TEMPERATURE; SCHOOL CHILD; STORAGE TEMPERATURE; TISSUE PRESERVATION; TISSUE SECTION;

FFPE; GLIOBLASTOMA; MIR-106A; PROGNOSIS; PROGNOSTIC MARKER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CHILD; FEMALE; GLIOBLASTOMA; HUMANS; IN SITU HYBRIDIZATION; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84878268595     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not001     Document Type: Article

References (49)

1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008; 359(5): 492-507.
2. Stupp R, Hegi ME, Neyns B, et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010; 28(16): 2712-2718.
3. Wang L, Wei Q, Wang LE, et al. Survival prediction in patients with glioblastoma multiforme by human telomerase genetic variation. J Clin Oncol. 2006; 24(10): 1627-1632.
4. Sumazin P, Yang X, Chiu HS, et al. An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. Cell. 2011; 147(2): 370-381.
5. Kasinski AL, Slack FJ. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer. 2011; 11(12): 849-864.
6. Camps C, Buffa FM, Colella S, et al. hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res. 2008; 14(5): 1340-1348.
7. Schwind S, Maharry K, Radmacher MD, et al. Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010; 28(36): 5257-5264.
8. Marchini S, Cavalieri D, Fruscio R, et al. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. Lancet Oncol. 2011; 12(3): 273-285.
9. Guan Y, Mizoguchi M, Yoshimoto K, et al. MiRNA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance. Clin Cancer Res. 2010; 16(16): 4289-4297.
10. Roth P, Wischhusen J, Happold C, et al. A specific miRNA signature in the peripheral blood of glioblastoma patients. J Neurochem. 2011; 118(3): 449-457.
11. Szafranska AE, Davison TS, Shingara J, et al. Accurate molecular characterization of formalin-fixed, paraffin-embedded tissues by microRNA expression profiling. J Mol Diagn. 2008; 10(5): 415-423.
12. Weng L, Wu X, Gao H, et al. MicroRNA profiling of clear cell renal cell carcinoma by whole-genome small RNA deep sequencing of paired frozen and formalin-fixed, paraffin-embedded tissue specimens. J Pathol. 2010; 222(1): 41-51.
13. Yang G, Zhang R, Chen X, et al. MiR-106a inhibits glioma cell growth by targeting E2F1 independent of p53 status. J Mol Med (Berl). 2011; 89(10): 1037-1050.
14. McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg. 2009; 110(1): 156-162.
15. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(t)) method. Methods. 2001; 25(4): 402-408.
16. Jiang L, Mao P, Song L, et al. MiR-182 as a prognostic marker for glioma progression and patient survival. Am J Pathol. 2010; 177(1): 29-38.
17. Donnem T, Eklo K, Berg T, et al. Prognostic impact of miR-155 in nonsmall cell lung cancer evaluated by in situ hybridization. J Transl Med. 2011; 9: 6.
18. Ali-Fehmi R, Che M, Khalifeh I, et al. The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma. Cancer. 2003; 98(7): 1423-1429.
19. Donnem T, Al-Saad S, Al-Shibli K, Busund LT, Bremnes RM. Co-expression of PDGF-B and VEGFR-3 strongly correlates with lymph node metastasis and poor survival in non-small-cell lung cancer. Ann Oncol. 2010; 21(2): 223-231.
20. Semaan A, Qazi AM, Seward S, et al. MicroRNA-101 inhibits growth of epithelial ovarian cancer by relieving chromatin-mediated transcriptional repression of p21(waf(1)/cip(1)). Pharma Res. 2011; 28(12): 3079-3090.
21. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008; 116(6): 597-602.
22. Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol. 2009; 27(34): 5743-5750.
23. Ma X, Yoshimoto K, Guan Y, et al. Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma. Neuro Oncol. 2012; 14(9): 1153-1162.
24. Faria MH, Goncalves BP, do Patrocinio RM, de Moraes-Filho MO, Rabenhorst SH. Expression of Ki-67, topoisomerase II alpha and c-MYC in astrocytic tumors: correlation with the histopathological grade and proliferative status. Neuropathology. 2006; 26(6): 519-527.
25. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin. 2010; 60(3): 166-193.
26. Purow B, Schiff D. Advances in the genetics of glioblastoma: are we reaching critical mass? Nat Rev Neurol. 2009; 5(8): 419-426.
27. Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009; 27(25): 4150-4154.
28. Riemenschneider MJ, Jeuken JW, Wesseling P, Reifenberger G. Molecular diagnostics of gliomas: state of the art. Acta Neuropathol. 2010; 120(5): 567-584.
29. Jansen M, Yip S, Louis DN. Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol. 2010; 9(7): 717-726.
30. Krex D, Klink B, Hartmann C, et al. Long-term survival with glioblastoma multiforme. Brain. 2007; 130(Pt 10): 2596-2606.
31. Tabatabai G, Stupp R, van den Bent MJ, et al. Molecular diagnostics of gliomas: the clinical perspective. Acta Neuropathol. 2010; 120(5): 585-592.
32. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2): 281-297.
33. Gu S, Jin L, Zhang F, Sarnow P, Kay MA. Biological basis for restriction of microRNA targets to the 3' untranslated region in mammalian mRNAs. Nat Struct Mol Biol. 2009; 16(2): 144-150.
34. Tricoli JV, Jacobson JW. MicroRNA: potential for cancer detection, diagnosis, and prognosis. Cancer Res. 2007; 67(10): 4553-4555.
35. Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer. 2010; 10(6): 389-402.
36. Suzuki HI, Miyazono K. Dynamics of microRNA biogenesis: crosstalk between p53 network and microRNA processing pathway. J Mol Med (Berl). 2010; 88(11): 1085-1094.
37. Calin GA, Ferracin M, Cimmino A, et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005; 353(17): 1793-1801.
38. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006; 9(3): 189-198.
39. Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008; 299(4): 425-436.
40. Yan LX, Huang XF, Shao Q, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA. 2008; 14(11): 2348-2360.
41. Gattolliat CH, Thomas L, Ciafre SA, et al. Expression of miR-487b and miR-410 encoded by 14q32.31 locus is a prognostic marker in neuroblastoma. Br J Cancer. 2011; 105(9): 1352-1361.
42. Zhi F, Chen X,Wang S, et al. The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma. Eur J Cancer. 2010; 46(9): 1640-1649.
43. Diaz R, Silva J, Garcia JM, et al. Deregulated expression of miR-106a predicts survival in human colon cancer patients. Genes Chromosomes Cancer. 2008; 47(9): 794-802.
44. Masuda N, Ohnishi T, Kawamoto S, Monden M, Okubo K. Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples. Nucleic Acids Res. 1999; 27(22): 4436-4443.
45. Lewis F, Maughan NJ, Smith V, Hillan K, Quirke P. Unlocking the archive - gene expression in paraffin-embedded tissue. J Pathol. 2001; 195(1): 66-71.
46. Huang WY, Sheehy TM, Moore LE, Hsing AW, Purdue MP. Simultaneous recovery of DNA and RNA from formalin-fixed paraffinembedded tissue and application in epidemiologic studies. Cancer Epidemiol Biomarkers Prev. 2010; 19(4): 973-977.
47. Li J, Smyth P, Flavin R, et al. Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol. 2007; 7: 36.
48. Xi Y, Nakajima G, Gavin E, et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA. 2007; 13(10): 1668-1674.
49. Doleshal M, Magotra AA, Choudhury B, Cannon BD, Labourier E, Szafranska AE. Evaluation and validation of total RNA extraction methods for microRNA expression analyses in formalin-fixed, paraffinembedded tissues. J Mol Diagn. 2008; 10(3): 203-211.